Bis(thiosemicarbazone) Complexes of Cobalt(III). Synthesis, Characterization, and Anticancer Potential.
暂无分享,去创建一个
Justin J. Wilson | S. MacMillan | A Paden King | Hendryck A Gellineau | Jung-Eun Ahn | Samantha N MacMillan | Justin J Wilson | J. Ahn | A. King | A. P. King | Justin J. Wilson | Hendryck A. Gellineau
[1] T. Storr,et al. Cobalt(III) complexes with 2-acetylpyridine-derived Schiff bases: Studies investigating ligand release upon reduction , 2017 .
[2] S. Radulović,et al. (Chalcogen)semicarbazones and their cobalt complexes differentiate HL-60 myeloid leukaemia cells and are cytotoxic towards tumor cell lines. , 2017, MedChemComm.
[3] C. Parkinson,et al. Cytotoxic activity of expanded coordination bis-thiosemicarbazones and copper complexes thereof , 2016, JBIC Journal of Biological Inorganic Chemistry.
[4] M. Hemann,et al. The Potent Inhibitory Effect of a Naproxen‐Appended Cobalt(III)‐Cyclam Complex on Cancer Stem Cells , 2016, Chembiochem : a European journal of chemical biology.
[5] V. Ferreira,et al. Investigation of cobalt(iii)-triazole systems as prototypes for hypoxia-activated drug delivery. , 2016, Dalton transactions.
[6] D. Richardson,et al. Zinc(II)-Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity. , 2016, Journal of medicinal chemistry.
[7] A. Banerjee,et al. Exploiting Copper Redox for (19)F Magnetic Resonance-Based Detection of Cellular Hypoxia. , 2016, Journal of the American Chemical Society.
[8] D. Richardson,et al. Identification of differential anti-neoplastic activity of copper bis(thiosemicarbazones) that is mediated by intracellular reactive oxygen species generation and lysosomal membrane permeabilization. , 2015, Journal of inorganic biochemistry.
[9] Nicole S. Bryce,et al. Cobalt(III) Chaperone Complexes of Curcumin: Photoreduction, Cellular Accumulation and Light-Selective Toxicity towards Tumour Cells. , 2015, Chemistry.
[10] Marie C. Heffern,et al. Tuning cobalt(III) Schiff base complexes as activated protein inhibitors. , 2015, Inorganic chemistry.
[11] K. Suntharalingam,et al. Advances in cobalt complexes as anticancer agents. , 2015, Dalton transactions.
[12] D. Richardson,et al. Di-2-pyridylketone 4,4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Multidrug Resistance by a Novel Mechanism Involving the Hijacking of Lysosomal P-Glycoprotein (Pgp)* , 2015, The Journal of Biological Chemistry.
[13] G. Sheldrick. SHELXT – Integrated space-group and crystal-structure determination , 2015, Acta crystallographica. Section A, Foundations and advances.
[14] A. McEwan,et al. Inhibition of respiratory complex I by copper(ii)-bis(thiosemicarbazonato) complexes. , 2014, Metallomics : integrated biometal science.
[15] A. Renfrew,et al. Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery. , 2014, Metallomics : integrated biometal science.
[16] S. Gaudet,et al. Cell-to-cell variability in cell death: can systems biology help us make sense of it all? , 2014, Cell Death and Disease.
[17] Ahmed Rezk,et al. Cytotoxic behavior and spectroscopic characterization of metal complexes of ethylacetoacetate bis(thiosemicarbazone) ligand. , 2014, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
[18] S. Allison,et al. Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors , 2014, British journal of pharmacology.
[19] Justin J. Wilson,et al. Synthetic methods for the preparation of platinum anticancer complexes. , 2013, Chemical reviews.
[20] Mohammad Fallahi-Sichani,et al. Metrics other than potency reveal systematic variation in responses to cancer drugs. , 2013, Nature chemical biology.
[21] Nicole S. Bryce,et al. Delivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study , 2013 .
[22] Mårten Fryknäs,et al. Effects of hypoxia on human cancer cell line chemosensitivity , 2013, BMC Cancer.
[23] W. Denny,et al. Cross-bridged cyclen or cyclam Co(III) complexes containing cytotoxic ligands as hypoxia-activated prodrugs. , 2013, Inorganic chemistry.
[24] Justin J. Wilson,et al. Monofunctional and higher-valent platinum anticancer agents. , 2013, Inorganic chemistry.
[25] Marie C. Heffern,et al. Cobalt derivatives as promising therapeutic agents. , 2013, Current opinion in chemical biology.
[26] K. Somasundaram,et al. In vitro and in vivo anticancer activity of copper bis(thiosemicarbazone) complexes. , 2013, Journal of medicinal chemistry.
[27] Marie C. Heffern,et al. Axial ligand exchange of N-heterocyclic cobalt(III) Schiff base complexes: molecular structure and NMR solution dynamics. , 2013, Inorganic chemistry.
[28] Nicole S. Bryce,et al. Dual targeting of hypoxic and acidic tumor environments with a cobalt(III) chaperone complex. , 2012, Journal of medicinal chemistry.
[29] S. Lippard,et al. Redox activation of metal-based prodrugs as a strategy for drug delivery. , 2012, Advanced drug delivery reviews.
[30] J. Dilworth,et al. Metal Complexes of Thiosemicarbazones for Imaging and Therapy , 2012 .
[31] Marie C. Heffern,et al. Specific inhibition of the transcription factor Ci by a cobalt(III) Schiff base-DNA conjugate. , 2012, Molecular pharmaceutics.
[32] P. Crouch,et al. An impaired mitochondrial electron transport chain increases retention of the hypoxia imaging agent diacetylbis(4-methylthiosemicarbazonato)copperII , 2011, Proceedings of the National Academy of Sciences.
[33] R. Gillies,et al. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. , 2011, Molecular pharmaceutics.
[34] Nicole S. Bryce,et al. Visualising the hypoxia selectivity of cobalt(III) prodrugs , 2011 .
[35] P. Crouch,et al. Mechanisms controlling the cellular accumulation of copper bis(thiosemicarbazonato) complexes. , 2011, Inorganic chemistry.
[36] P. Donnelly,et al. Copper Complexes of Bis(thiosemicarbazones): From Chemotherapeutics to Diagnostic and Therapeutic Radiopharmaceuticals , 2011 .
[37] W. Berger,et al. Anticancer activity of metal complexes: involvement of redox processes. , 2011, Antioxidants & redox signaling.
[38] D. Richardson,et al. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. , 2011, Cancer research.
[39] W. Wilson,et al. Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.
[40] W. Denny,et al. Syntheses of 8-quinolinolatocobalt(III) complexes containing cyclen based auxiliary ligands as models for hypoxia-activated prodrugs. , 2010, Dalton transactions.
[41] John E. Bercaw,et al. NMR Chemical Shifts of Trace Impurities: Common Laboratory Solvents, Organics, and Gases in Deuterated Solvents Relevant to the Organometallic Chemist , 2010 .
[42] D. Richardson,et al. Thiosemicarbazones: the new wave in cancer treatment. , 2009, Future medicinal chemistry.
[43] T. Meade,et al. Targeted inhibition of Snail family zinc finger transcription factors by oligonucleotide-Co(III) Schiff base conjugate , 2009, Proceedings of the National Academy of Sciences.
[44] P. Müller. Practical suggestions for better crystal structures , 2009 .
[45] T. Hambley. Physiological Targeting to Improve Anticancer Drug Selectivity , 2008 .
[46] A. Argyriou,et al. A review on oxaliplatin-induced peripheral nerve damage. , 2008, Cancer treatment reviews.
[47] Q. Le,et al. Clinical biomarkers for hypoxia targeting , 2008, Cancer and Metastasis Reviews.
[48] B. Keppler,et al. Electron-transfer activated metal-based anticancer drugs , 2008 .
[49] Trevor W. Hambley,et al. Cellular uptake and distribution of cobalt complexes of fluorescent ligands , 2008, JBIC Journal of Biological Inorganic Chemistry.
[50] A. G. Wedd,et al. Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. insights into mechanisms of copper uptake and hypoxia selectivity. , 2008, Inorganic chemistry.
[51] R. Gust,et al. Cellular uptake quantification of metalated peptide and peptide nucleic acid bioconjugates by atomic absorption spectroscopy. , 2008, Angewandte Chemie.
[52] Jason S. Lewis,et al. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. , 2007, Dalton transactions.
[53] M. Hall,et al. Bioreductive activation and drug chaperoning in cobalt pharmaceuticals. , 2007, Dalton transactions.
[54] K. Nugent,et al. Cisplatin Nephrotoxicity: A Review , 2007, The American journal of the medical sciences.
[55] D. Richardson,et al. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. , 2006, Journal of medicinal chemistry.
[56] J. Yi,et al. Synthesis and crystal structure of some transition metal complexes with a novel bis-Schiff base ligand and their antitumor activities. , 2006, European journal of medicinal chemistry.
[57] Mika Kettunen,et al. Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. , 2006, Current medicinal chemistry.
[58] C. Ling,et al. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. , 2005, Nuclear medicine and biology.
[59] J. Joyce,et al. Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.
[60] L. Helm,et al. Inorganic and bioinorganic solvent exchange mechanisms. , 2005, Chemical reviews.
[61] R. Gust,et al. Development of cobalt(3,4-diarylsalen) complexes as tumor therapeutics. , 2004, Journal of medicinal chemistry.
[62] C. Reynolds,et al. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. , 2002, Journal of medicinal chemistry.
[63] Jason S. Lewis,et al. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships , 2002, JBIC Journal of Biological Inorganic Chemistry.
[64] Nobuyuki Oyama,et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells , 2001, Annals of nuclear medicine.
[65] A. W. Addison,et al. Conversion constants for redox potentials measured versus different reference electrodes in acetonitrile solutions at 25°C , 2000 .
[66] M. McKeage,et al. Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. , 1999, Journal of inorganic biochemistry.
[67] H. Gray,et al. Inhibition of thermolysin and human α-thrombin by cobalt(III) Schiff base complexes , 1999 .
[68] M. Simon,et al. Selective Inhibition of Human α-Thrombin by Cobalt(III) Schiff Base Complexes , 1998 .
[69] E. Cvitkovic. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. , 1998, Cancer treatment reviews.
[70] L. Frydman,et al. Solid and liquid phase 59Co NMR studies of cobalamins and their derivatives. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[71] H. Gray,et al. Spectroscopy and Electrochemistry of Cobalt(III) Schiff Base Complexes , 1997 .
[72] Neil G. Connelly,et al. Chemical Redox Agents for Organometallic Chemistry. , 1996, Chemical reviews.
[73] A. Yamasaki. Cobalt-59 Nuclear Magnetic Resonance Spectroscopy in Coordination Chemistry , 1991 .
[74] A. B. P. Lever,et al. Electrochemical parametrization of metal complex redox potentials, using the ruthenium(III)/ruthenium(II) couple to generate a ligand electrochemical series , 1990 .
[75] G. Navon,et al. Spectroscopic and solution properties of the cobalt(III) hexaimidazole ion , 1989 .
[76] J. Mason. Patterns of nuclear magnetic shielding of transition-metal nuclei , 1987 .
[77] M. Lemmon,et al. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. , 1986, International journal of radiation oncology, biology, physics.
[78] M. Brorson,et al. Cobalt-59 NMR chemical shifts of cobalt(III) complexes; correlations with parameters calculated from ligand-field spectra , 1985 .
[79] C. H. Bayley,et al. THE PREPARATION OF SOME THIOSEMICARBAZONES AND THEIR COPPER COMPLEXES: PART III , 1960 .
[80] B. L. Freedlander,et al. Carcinostatic action of polycarbonyl compounds and their derivatives. IV. Glyoxal bis (thiosemicarbazone) and derivatives. , 1958, Cancer research.
[81] S. Williamson,et al. Tirapazamine: a novel agent targeting hypoxic tumor cells. , 2009, Expert opinion on investigational drugs.
[82] M. Jakupec,et al. Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. , 2009, Journal of analytical atomic spectrometry.
[83] G. Sheldrick. A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.
[84] G. Daugaard,et al. Cisplatin nephrotoxicity , 2004, Cancer Chemotherapy and Pharmacology.
[85] S. Merajver,et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[86] Jason S. Lewis,et al. Redox-active metal complexes for imaging hypoxic tissues: structure–activity relationships in copper(II) bis(thiosemicarbazone) complexes , 1998 .
[87] M Iturralde Navarro,et al. [Culture of animal cells]. , 1984, Medicina clinica.
[88] E. Blanz,et al. Chemotherapy studies on transplanted mouse tumors. VIII. , 1963, Cancer research. Supplement.
[89] B. L. Freedlander. Chemotherapy studies on transplanted mouse tumors. , 1955, Cancer research.
[90] R. J. P. Williams,et al. 637. The stability of transition-metal complexes , 1953 .